Explore

Review Highlights Probiotic Potential for Mental Health, Identifies Research Gaps

Review Highlights Probiotic Potential for Mental Health, Identifies Research Gaps

A recent narrative review published in the Journal of Restorative Medicine synthesized clinical and translational evidence on probiotic interventions for mental health conditions, including anxiety, depression, bipolar disorder, and schizophrenia. The review explored proposed gut-brain mechanisms, such as neurotransmitter modulation, immune regulation, inflammation reduction, short-chain fatty acid production, and improved gut barrier function. Specific probiotic species, particularly Lactobacillus and Bifidobacterium, have been linked to improvements in various clinical outcomes. For instance, Lactobacillus plantarum DR7 and P-8 were associated with lower cortisol and inflammatory markers and psychological improvements in depression, while Bifidobacterium animalis subsp. lactis BB-12 showed improvements in anxiety. However, the review also noted considerable differences between studies in terms of strains, doses, populations, durations, and outcome measures, which limit the clinical applicability and iden...

Long-Term Study Links Over 150 Minutes Daily Social Media Use to Higher Depression Rates in U.S. Adults

Long-Term Study Links Over 150 Minutes Daily Social Media Use to Higher Depression Rates in U.S. Adults

A comprehensive long-term study published in the journal npj Mental Health Research has found a consistent correlation between increased daily social media use and higher rates of self-reported depression among U.S. adults. The research, which analyzed 11 separate yearly surveys from 2014 to 2024, involved over 180,000 participants aged 18 to 70. The study identified a 'tipping point' around 150 minutes (two and a half hours) of daily social media use, beyond which the link to depression became notably stronger. While the study acknowledges it cannot prove causation, it consistently showed that social media use became a more prominent predictor of depression in later years, even surpassing other digital activities like gaming, TV, and email in its predictive strength in some models. The findings remained consistent across different presidential administrations and the rise of various social media platforms, suggesting a robust and enduring association.

Scrolling social media for this long linked to depression, study finds

Scrolling social media for this long linked to depression, study finds

It's likely not a surprise to many that too much social media can put you in a bad mood — but where is the cutoff? This new study took a closer look.

Research Reveals Inconsistent Effects of Longevity Interventions on Epigenetic Aging Markers

Research Reveals Inconsistent Effects of Longevity Interventions on Epigenetic Aging Markers

A new analysis conducted by researchers at Yale University and collaborators, published in Nature Medicine, indicates that over half of 51 human longevity intervention studies showed no significant effect on epigenetic aging clocks. The study pooled 3,128 blood samples and calculated 16 prominent epigenetic clocks and 94 additional DNA methylation biomarkers. While 19 interventions initially showed a decrease in epigenetic age, this number dropped to 13 after statistical correction. Conversely, five interventions significantly increased epigenetic age, and 26 showed no significant effect. A key finding highlighted the inconsistency of senolytics, a class of compounds aimed at clearing senescent cells, with different biomarkers moving in opposite directions within and across studies. The researchers proposed two rules for a genuine intervention: biomarkers of the same generation should move in the same direction and magnitude within a study, and a second study of the same intervention should show similar mo...

10x Genomics Launches Atera Platform for Whole-Transcriptome Spatial Analysis

10x Genomics Launches Atera Platform for Whole-Transcriptome Spatial Analysis

10x Genomics has introduced Atera, a new spatial platform designed to measure the entire transcriptome with single-cell sensitivity and at a significantly larger scale. This launch marks a continued expansion of 10x Genomics' focus on spatial biology, following its earlier contributions to the single-cell revolution. According to Serge Saxonov, co-founder and CEO of 10x Genomics, customer shipments for the Atera platform are anticipated to commence later this year. Saxonov emphasizes that spatial biology is evolving beyond a niche research area, becoming a crucial method for integrating molecular, cellular, and tissue-level insights. The company's strategy involves developing advanced tools for biological measurement and addressing biological questions by working backward from them, rather than being solely driven by specific technologies. This approach has also led 10x Genomics into proteomics, with a belief that binder-based methods currently offer the most effective path to scalability. Furthermore, the...

Stanford Director Michael Snyder Advocates for Health Tracking Over Disease Tracking with Wearables and AI

Stanford Director Michael Snyder Advocates for Health Tracking Over Disease Tracking with Wearables and AI

Michael Snyder, Director of the Center for Genomics and Personalized Medicine at Stanford University, is a strong proponent of using health-tracking wearables and AI to shift healthcare from a 'sickcare' model to a proactive 'healthcare' model. Snyder, who personally uses multiple wearables, believes these devices can provide continuous, longitudinal health data, enabling early detection of health shifts before symptoms appear. His research has shown that wearables can detect illnesses like Lyme disease and COVID-19 presymptomatically. He also highlights the potential of continuous glucose monitoring (CGM) to reveal glucose spikes in seemingly normal individuals, influencing dietary choices. Snyder is leading an ARPA-H project to develop an FDA-approved 'intrinsic capacity' score, a quantitative measure of health and wellness, and a home test for frequent, affordable health monitoring, aiming for a cost of around $100.

GlaxoSmithKline Initiates Phase 3 Clinical Study for mRNA Flu Vaccine in Erie, Pennsylvania

GlaxoSmithKline Initiates Phase 3 Clinical Study for mRNA Flu Vaccine in Erie, Pennsylvania

GlaxoSmithKline (GSK) is launching a nationwide Phase 3 clinical study for its new mRNA flu vaccine, with Erie, Pennsylvania, serving as one of the study sites. The study aims to enroll 75 participants aged 65 and older who are in general good health. Participants will receive either the new mRNA vaccine or a high-dose traditional flu vaccine, as there is no placebo group. The first doses are expected to be administered by mid-September at AHN Primary Care — Central Erie, under the supervision of Dr. Brad Fox, the study's principal investigator. Unlike traditional vaccines that use weakened or partial viruses, mRNA vaccines deliver genetic instructions to teach the body to produce a harmless viral protein and mount an immune response. This technology allows for faster production, taking two to three months compared to six to eight months for traditional flu vaccines. Early clinical data suggests the GSK mRNA flu vaccine may be 25% to 30% more effective than traditional flu vaccines, with comparable safety ...

Neurovalens Receives FDA De Novo Approval for Modius Spero PTSD Treatment

Neurovalens Receives FDA De Novo Approval for Modius Spero PTSD Treatment

Neurovalens, a biotechnology company specializing in non-invasive neuro-technology, has announced the publication of peer-reviewed research in Nature Mental Health detailing the effectiveness of its Modius Spero device for treating symptoms associated with Post-traumatic Stress Disorder (PTSD). The device, which uses low-level electrical pulses to stimulate areas of the brain regulating stress response, recently received De Novo approval from the U.S. Food & Drug Administration (FDA). This approval allows Modius Spero to be prescribed to veterans through the U.S. Department of Veterans Affairs (VA). The clinical trial, conducted by the University of California, San Diego, involved 383 U.S. adults with PTSD and demonstrated statistically and clinically significant reductions in both PTSD symptom severity and insomnia. This marks a significant development in providing a non-invasive, at-home treatment option for individuals living with PTSD.

Experts Advise on Sustaining Digital Detox Benefits Beyond Short-Term Abstinence

Experts Advise on Sustaining Digital Detox Benefits Beyond Short-Term Abstinence

Experts Advise on Sustaining Digital Detox Benefits Beyond Short-Term Abstinence

Hormone Replacement Therapy Linked to Reduced Dementia Risk, Influenced by Menopause Type and Timing

Hormone Replacement Therapy Linked to Reduced Dementia Risk, Influenced by Menopause Type and Timing

A large UK Biobank analysis has revealed that hormone replacement therapy (HRT) use is associated with a modest reduction in dementia risk, with the association being more pronounced in certain subgroups of postmenopausal women. The study, published in the journal Alzheimer’s & Dementia, included 183,450 postmenopausal women and found a 10% reduction in the risk of all-cause dementia among HRT users. This reduction was stronger in women who experienced surgical menopause (26% lower risk) and those with less than 37 years of endogenous estrogen exposure (16% lower risk). The timing of HRT initiation also played a significant role, with the risk of dementia reduced when HRT was started between the ages of 46 and 56 years. For women with natural menopause, the risk was reduced by 18% only when HRT was started at 51-56 years. In contrast, for surgical menopause, an increasingly stronger association with lower dementia risk was observed with later HRT initiation within the 46-56 age range. The study also noted ...

Hormone Replacement Therapy Linked to Reduced Dementia Risk in Specific Postmenopausal Women

Hormone Replacement Therapy Linked to Reduced Dementia Risk in Specific Postmenopausal Women

A large-scale study conducted by the University of East Anglia and the University of Exeter indicates that Hormone Replacement Therapy (HRT) may reduce the risk of dementia, particularly for certain groups of postmenopausal women. The research, which tracked over 180,000 postmenopausal women in the UK, found that HRT users had a 16% lower risk of developing Alzheimer's disease compared to non-users. The most significant reduction, 26%, was observed in women who had undergone surgical menopause. Additionally, women with naturally lower lifetime estrogen exposure (due to late onset of periods or early menopause) showed a 16% lower risk of any type of dementia with HRT use. The study also highlighted that women carrying the APOE4 gene variant, a known risk factor for Alzheimer's, experienced stronger benefits from HRT. The optimal age for initiating HRT for dementia risk reduction was identified as between 46 and 56, supporting the 'critical window' hypothesis.

Earlier Menopause Age Linked to Faster Brain Atrophy and Increased Dementia Risk

Earlier Menopause Age Linked to Faster Brain Atrophy and Increased Dementia Risk

New research indicates that an earlier age at menopause is associated with faster cognitive decline, earlier onset of Alzheimer's disease (AD), and a greater accumulation of white matter hyperintensities in older women. This association is particularly evident following spontaneous menopause. A longitudinal cohort study of 2,603 older women, utilizing data from the Religious Orders Study and Rush Memory and Aging Project with up to 18 years of follow-up, examined the relationship between menopause age and cognitive decline, AD onset, and structural brain changes. The findings suggest that menopause age can serve as a midlife-identifiable marker for dementia risk stratification. Earlier menopause was linked to faster global cognitive decline and episodic memory decline, as well as an earlier AD diagnosis. For women with spontaneous menopause, earlier menopause was associated with a faster accumulation of white matter hyperintensity volume, with a 5-year earlier menopause leading to approximately 15% greater...